Hims & Hers Health (NYSE:HIMS) has launched access to Novo Nordisk FDA-approved GLP-1 medications for eligible patients. The offering includes a range of GLP-1 options, including the only pill currently approved for weight loss. The company also introduced a new weight loss membership that combines medication access with broader support services.
Hims & Hers Health focuses on telehealth and subscription based care, and GLP-1 weight loss treatments have become a key area of interest for both patients and investors. By working with Novo Nordisk on FDA-approved GLP-1 medications, the platform is adding a high profile therapy class to its existing portfolio of treatments. For readers watching NYSE:HIMS, this move ties the company more closely to one of the most closely watched areas in consumer health.
The new weight loss membership combines recurring revenue potential with deeper engagement, as customers commit to an ongoing program rather than one off visits. For investors, the development raises questions around how GLP-1 offerings might affect user growth, margins, and differentiation versus other digital health providers.
Stay updated on the most important news stories for Hims & Hers Health by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Hims & Hers Health.
NYSE:HIMS Earnings & Revenue Growth as at Mar 2026
3 things going right for Hims & Hers Health that this headline doesn’t cover.
Quick Assessment ✅ Price vs Analyst Target: At US$18.78, Hims & Hers Health trades about 22% below the US$24.15 analyst price target. ✅ Simply Wall St Valuation: Shares are described as trading roughly 67.5% below estimated fair value, which suggests a large valuation gap. ✅ Recent Momentum: The 30 day return of about 29.3% points to strong short term interest in the stock.
There is only one way to know the right time to buy, sell or hold Hims & Hers Health. Head to Simply Wall St’s
company report for the latest analysis of Hims & Hers Health’s Fair Value.
Key Considerations 📊 The Novo Nordisk GLP-1 launch and weight loss membership link Hims & Hers more closely to a fast growing therapy category that could influence revenue mix and brand positioning. 📊 Monitor how GLP-1 membership uptake affects subscription growth, margins and any updates to the current P/E of about 33.3x compared with the Healthcare industry average of roughly 21.7x. ⚠️ Shares have been highly volatile over the past 3 months, so position sizing and risk tolerance may be important if the GLP-1 rollout coincides with sharp price swings. Dig Deeper
For the full picture, including more risks and potential rewards, check out the
complete Hims & Hers Health analysis. Alternatively, you can visit the
community page for Hims & Hers Health to see how other investors believe this latest news will affect the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it.
Discover if Hims & Hers Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com